Clinical trial of nebulized disodium cromoglycate on an asthmatic child with 18q- syndrome who showed involuntary movement by theophylline

概要

論文の詳細を見る
A 2-year-old girl with asthma, who had developmental delay originated in 18q- syndrome, showed involuntary movement in spite of low serum concentration of the drug when she ingested 10mg/kg/day slow-release theophylline.She also had signs of intoxication for oral β-adrenergic agonists, including restlessness and insomnia. Although she behaved violently whenever nebuliser inhalation was performed, daily inhalation therapy with disodium cromoglycate (DSCG) using ultrasonic nebuliser must be introduced instead of oral medications because she had continuous moderate asthmatic attack. After the treatment with DSCG was started, her asthma score has remarkably improved and she has been able to participate in training for mental and physical development. Her plasma concentrations of DSCG measured by high performance liquid chromatography at 5 and 30min after inhalation of DSCG were equal to mean levels of DSCG in asthmatic children with normal development who were improved by treatment with DSCG inhalation, suggesting that inhalation therapy was effective. It was also effective for her to increase dosage of DSCG when she had frequent asthmatic attacks again during therapy with common dose of DSCG was performed.
日本小児アレルギー学会の論文